A phase I trial of of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
Anthony B. El-Khoueiry
Consultant or Advisory Role - Bayer/Onyx
Honoraria - Bayer/Onyx
Research Funding - Bayer/Onyx
Robert O'Donnell
No relevant relationships to disclose
Philip C. Mack
No relevant relationships to disclose
Suzette Blanchard
No relevant relationships to disclose
Nathan Bahary
No relevant relationships to disclose
Yixing Jiang
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Helen X. Chen
No relevant relationships to disclose
Heinz-Josef Lenz
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer
David R. Gandara
No relevant relationships to disclose